cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561	NDA	Gilead Sciences, Inc.	61958-1901-1	30 TABLET in 1 BOTTLE, PLASTIC (61958-1901-1)	2015-11-05
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the current supply chain landscape for the active pharmaceutical ingredients (APIs) comprising the fixed-dose combination therapy for HIV: Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate. Analysis focuses on key manufacturers, geographic concentrations, patent expiry timelines, and potential supply risks.

Who Are the Primary Manufacturers of These APIs?

The production of Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate is dominated by a limited number of specialized pharmaceutical manufacturers. These entities possess the requisite technical expertise, regulatory compliance infrastructure, and production capacity to synthesize these complex molecules.

Emtricitabine and Tenofovir Alafenamide Fumarate: These nucleoside reverse transcriptase inhibitors (NRTIs) are often produced by the originator, Gilead Sciences, through its contract manufacturing organizations (CMOs). However, as patent protections wane, generic API manufacturers are increasingly entering the market.
Elvitegravir and Cobicistat: Elvitegravir, an integrase strand transfer inhibitor (INSTI), and Cobicistat, a pharmacokinetic enhancer (a "booster"), are also primarily manufactured by the originator and its designated partners. Generic API production for these components is also emerging.

Key API suppliers identified through market intelligence and regulatory filings include:

Gilead Sciences: The originator of these APIs, with significant internal manufacturing and reliance on strategic CMOs.
Hetero Drugs Limited: A significant Indian API manufacturer with a broad portfolio including antiretrovirals.
Laurus Labs: Another prominent Indian pharmaceutical company specializing in API development and manufacturing, including HIV therapeutics.
Divi’s Laboratories: An Indian API producer with capabilities in complex chemical synthesis.
Viatris (formerly Mylan): A global pharmaceutical company with a robust generics business, including API manufacturing.

These manufacturers operate under strict Good Manufacturing Practice (GMP) guidelines and are subject to inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

What Are the Key Geographic Concentrations for API Production?

API manufacturing for Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate exhibits a significant geographic concentration, primarily in Asia, with India emerging as a dominant hub.

India: This region holds a substantial share of global API production for these antivirals. Indian manufacturers benefit from established chemical synthesis expertise, cost-effective labor, and a well-developed pharmaceutical infrastructure. Key manufacturing sites are concentrated in states like Andhra Pradesh, Telangana, and Gujarat.
China: While India is a primary focus, China also plays a role in the global supply chain, particularly for certain intermediates or precursor chemicals used in the synthesis of these APIs. Chinese manufacturers are subject to evolving environmental regulations and quality control standards.
United States and Europe: While historically strong in pharmaceutical manufacturing, the production of bulk APIs for high-volume generic drugs has largely shifted to Asia due to cost advantages. However, some specialized manufacturing, process development, and niche API production may still occur in these regions.

The concentration in specific geographies creates potential vulnerabilities related to geopolitical stability, trade policies, and localized environmental or health crises.

What Are the Patent Expiry Timelines for These APIs?

The patent landscape for Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate is critical for understanding market entry for generic manufacturers and potential price erosion.

Emtricitabine and Tenofovir Alafenamide Fumarate: These are components of established HIV treatments. Key patents for Emtricitabine and earlier forms of Tenofovir (like Tenofovir Disoproxil Fumarate) have expired. Patents specifically covering Tenofovir Alafenamide Fumarate and its formulations have later expiry dates.
- US Patent 10,415,560 (Tenofovir Alafenamide Fumarate) has a listed expiration in 2028, subject to patent term extensions and potential challenges [1].
- US Patent 8,890,895 (Emtricitabine) has expired.
Elvitegravir: As a more recent INSTI, Elvitegravir patents extend further.
- US Patent 8,097,605 (Elvitegravir) is set to expire in 2028, with potential for extension [1].
Cobicistat: This booster molecule's patents also have significant terms remaining.
- US Patent 8,097,605 (Elvitegravir and Cobicistat co-formulation patents, often linked) have expiration dates around 2028, subject to extensions and challenges [1].

Table 1: Indicative Patent Expiry for Key APIs (USA)

API	Relevant US Patent(s)	Indicative Expiry Date	Notes
Emtricitabine	Expired	N/A	Key composition of matter patents expired
Tenofovir Alafenamide Fumarate	10,415,560	~2028	Subject to Patent Term Extension (PTE)
Elvitegravir	8,097,605	~2028	Subject to PTE
Cobicistat	8,097,605	~2028	Often linked to Elvitegravir formulation patents

These dates represent an approximation. The actual expiry dates for market entry by generic manufacturers can be influenced by patent term extensions (PTE), data exclusivity periods, and successful patent litigation or challenges. The emergence of Paragraph IV certifications in the US can significantly accelerate generic competition.

What Are the Potential Supply Chain Risks for These APIs?

The supply chain for Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate presents several potential risks that could impact availability and cost.

Geopolitical Instability: The high concentration of API manufacturing in India and China exposes the supply chain to risks associated with regional conflicts, trade disputes, and protectionist policies. Disruptions in these regions can have a cascading effect globally.
Regulatory Changes and Compliance: Evolving environmental regulations, stricter quality control mandates, and unexpected inspections in manufacturing countries can lead to production slowdowns or temporary shutdowns.
Raw Material Sourcing: The synthesis of these complex APIs relies on a sophisticated network of intermediate suppliers. Disruptions in the supply of key raw materials, whether due to single-source dependencies or global shortages, can halt API production.
Manufacturing Capacity Constraints: While capacity exists, sudden surges in demand or unexpected plant closures (due to accidents, natural disasters, or quality issues) can lead to shortages. The qualification of new API manufacturers by pharmaceutical companies is a lengthy process, limiting rapid substitution.
Intellectual Property Litigation: Ongoing patent disputes and challenges, particularly Paragraph IV filings in the U.S., can create uncertainty. While intended to promote competition, litigation can sometimes lead to temporary supply disruptions or market entry delays.
Logistical Challenges: Global shipping delays, increased freight costs, and port congestion can impact the timely delivery of APIs to formulation sites, affecting drug availability.
Quality Control Failures: Any lapse in GMP compliance by a major API manufacturer can lead to product recalls, batch rejections, and significant supply disruptions, necessitating the qualification of alternative suppliers.

How Do the Manufacturing Processes for These APIs Differ?

The synthesis of each API involves distinct chemical pathways, requiring specialized equipment and expertise.

Emtricitabine: This is a synthetic nucleoside analog. Its synthesis involves complex chiral chemistry to ensure the correct stereoisomer is produced, which is critical for its pharmacological activity. Key steps often involve nucleoside coupling and functional group modifications.
Tenofovir Alafenamide Fumarate (TAF): TAF is a prodrug of Tenofovir, designed for improved intracellular delivery and reduced systemic toxicity compared to its predecessor, Tenofovir Disoproxil Fumarate (TDF). Its synthesis involves the phosphonamidate chemistry, which is more complex than TDF synthesis and requires careful control of reaction conditions and purification steps to yield the desired chiral product.
Elvitegravir: This is a benzothiophene-based integrase inhibitor. Its synthesis involves multi-step organic reactions, often including heterocyclic chemistry and palladium-catalyzed coupling reactions, to construct the core molecular structure. Precise control of stereochemistry and regioselectivity is crucial.
Cobicistat: Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A) enzymes. Its synthesis involves forming a thiazole ring and incorporating specific functional groups. The process requires careful handling of reagents and intermediates, often involving Grignard reactions or similar organometallic chemistry.

While specific proprietary manufacturing routes vary between companies, the general chemical transformations and purification techniques are established. Generic API manufacturers must develop processes that are non-infringing on existing patents while achieving the same purity and quality standards as the originator.

What is the Competitive Landscape for Generic API Supply?

The competitive landscape for the generic API supply of these four components is evolving, driven by impending patent expiries and the established presence of large Indian API manufacturers.

Emtricitabine and Tenofovir Alafenamide Fumarate: These have seen the most activity in terms of generic development. Manufacturers like Hetero Drugs, Laurus Labs, and Divi's Laboratories are well-positioned to supply these APIs to the global generic market once patents fully expire or are successfully challenged.
Elvitegravir and Cobicistat: Generic competition for these components is emerging but is generally at an earlier stage compared to the nucleoside analogs. The complexity of their synthesis and the later patent expiries contribute to this. Companies that have demonstrated expertise in INSTI and booster synthesis are likely to lead this segment.
Integrated API/Formulation Players: Some pharmaceutical companies operate as both API manufacturers and finished dosage form (FDF) producers. These entities can offer integrated solutions, potentially leading to cost efficiencies and supply chain reliability for generic drug products. Viatris is an example of such a company.
Limited Number of Qualified Suppliers: Despite the growing number of potential generic manufacturers, the number of APIs that meet the stringent quality and regulatory requirements of major pharmaceutical markets (FDA, EMA) remains limited. This can create concentrated supply points even within the generic space.

The intensity of generic competition will directly correlate with the ease of synthesis, the strength and breadth of remaining patent protection, and the regulatory pathways available for approval.

Key Takeaways

The supply chain for Cobicistat, Elvitegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate is characterized by a concentrated manufacturing base in India, with patent expiries creating opportunities for generic API producers. Geopolitical risks, regulatory shifts, and raw material dependency are significant supply chain vulnerabilities. Manufacturers must navigate complex synthesis routes and rigorous quality standards to compete.

Frequently Asked Questions

What is the current status of patent challenges for Tenofovir Alafenamide Fumarate in the U.S.? Paragraph IV certifications have been filed by generic manufacturers challenging key patents for Tenofovir Alafenamide Fumarate, indicating potential for earlier generic market entry than the nominal expiry dates suggest.
Are there any single-source dependencies for critical intermediates in the synthesis of these APIs? While specific intermediate supplier lists are proprietary, the multi-step synthesis of these complex molecules often involves reliance on a limited number of specialized chemical suppliers for certain advanced intermediates, posing a potential single-source risk.
How do regulatory approvals for generic API manufacturers differ across major markets like the U.S. and Europe? Both the U.S. FDA and the EMA require Drug Master Files (DMFs) detailing the API manufacturing process, quality control, and stability data. While the core requirements are similar, specific inspection protocols and data submission formats can differ, necessitating tailored regulatory strategies for each market.
What impact has recent global supply chain disruption, such as shipping container shortages, had on the delivery of these APIs? Recent disruptions have led to increased lead times for API shipments and higher freight costs. Manufacturers have responded by increasing inventory levels and exploring alternative shipping routes, though this does not fully mitigate the risk of delays.
How does the development of new HIV treatment modalities, such as long-acting injectables, affect the long-term demand for these oral APIs? While long-acting injectables represent an innovation, oral fixed-dose combinations remain the standard of care for a significant patient population. The market share shift will likely be gradual, and demand for these oral APIs is expected to remain substantial for the foreseeable future, particularly in resource-limited settings.

Citations

[1] U.S. Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from https://patft.uspto.gov/

Suppliers and packagers for generic pharmaceutical drug: cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate